The sale is small relative to market cap and appears to be a tax-withholding sale tied to equity vesting, not a discretionary insider reduction. Monitor for any subsequent Form 4 filings to confirm execution and for any larger insider sales that could signal a change in sentiment.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $2.53entry
- T+1 · 7d ago −3.16%α −2.79% · $2.45
- T+5 · 20h ago −14.62%α −12.93% · $2.16
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sarbani Chaudhuri, an officer of Rocket Pharmaceuticals, filed a Form 144 notice of intent to sell 4,872 shares of common stock with an approximate market value of $11,335. The shares were acquired via restricted stock vesting on November 5, 2026. The filing notes that the sale includes shares needed to cover a tax obligation from the vesting of an equity award, indicating this is a routine tax-related sale rather than a discretionary portfolio reduction.
Key Facts
- Officer Sarbani Chaudhuri filed Form 144 to sell 4,872 shares of common stock
- Estimated aggregate market value of shares: $11,335.20
- Shares acquired via restricted stock vesting on November 5, 2026
- Sale includes shares to cover tax obligation from vested equity award
- Sale intended to be executed on or about November 9, 2026 on Nasdaq
- Company market cap is approximately $267M; proposed sale represents ~0.004% of market cap
Financial Impact
Proposed sale of 4,872 shares valued at approximately $11,335, representing about 0.004% of the company's $267M market cap
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur
- No information on the officer's total holdings to assess proportionality of this sale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007867 |
| Document: 0001959173-26-007867-index.html | 0001959173-26-007867 |
| Document: 0001959173-26-007867.txt | 0001959173-26-007867 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers